US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Drugs Made in America Acquisition Corp. II

10.16

+0.00010.00%

Volume:462

Turnover:5K

Market Cap:666.25M

PE:75.39

High:10.17

Open:10.16

Low:10.16

Close:10.16

52wk High:10.80

52wk Low:9.94

Shares:65.58M

Float Shares:50.00M

Volume Ratio:6.90

T/O Rate:0.00%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.1348

ROE:--

ROA:-0.32%

PB:-37.40

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Drugs Made in America Acquisition II swings to Q1 FY26 net income of $4.34 million

Drugs Made in America Acquisition II posts FY25 net income of $4.2 million

Drugs Made in America Acquisition II issues $1.4 million convertible notes financing deal

Drugs Made in America Acquisition II delays annual report filing, targets April 15 deadline

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/DMIIU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"DMIIU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DMIIU\",,,,,undefined,":{"symbol":"DMIIU","market":"US","secType":"STK","nameCN":"Drugs Made in America Acquisition Corp. II","latestPrice":10.1601,"timestamp":1782244800000,"preClose":10.16,"halted":0,"volume":462,"delay":0,"changeRate":0.000009842519685016432,"floatShares":50000000,"shares":65575000,"eps":0.13475977,"marketStatus":"Closed","change":0.0001,"latestTime":"06-23 16:00:00 EDT","open":10.16,"high":10.1748,"low":10.16,"amount":4695,"amplitude":0.001457,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.13475977,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1782288000000},"marketStatusCode":5,"adr":0,"listingDate":1758772800000,"exchange":"NASDAQ","adjPreClose":10.16,"volumeRatio":6.895517},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DMIIU\",,,,,undefined,":{"symbol":"DMIIU","floatShares":50000000,"roa":"-0.32%","roe":"--","lyrEps":0,"volumeRatio":6.895517,"shares":65575000,"dividePrice":0,"high":10.1748,"amplitude":0.001457,"preClose":10.16,"low":10.16,"week52Low":9.935,"pbRate":"-37.40","week52High":10.8,"institutionHeld":0,"latestPrice":10.1601,"eps":0.13475977,"divideRate":0,"volume":462,"delay":0,"ttmEps":0.13475977,"open":10.16,"prevYearClose":10.015,"prevWeekClose":10.12,"prevMonthClose":10.155,"prevQuarterClose":10.04,"fiveDayClose":10.12,"twentyDayClose":10.155,"sixtyDayClose":10.02},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DMIIU\",params:#limit:5,,,undefined,":[{"date":"2026-05-14","symbol":"DMIIU","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1778788800000,"name":null,"time":"Post Market","dateTimestamp":1778731200000,"actualEps":null},{"date":"2026-04-15","symbol":"DMIIU","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1776283200000,"name":null,"time":"Post Market","dateTimestamp":1776225600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DMIIU\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DMIIU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DMIIU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2635725101","title":"Drugs Made in America Acquisition II swings to Q1 FY26 net income of $4.34 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635725101","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635725101?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:22","pubTimestamp":1778790161,"startTime":"0","endTime":"0","summary":"Drugs Made in America Acquisition II posted net income of USD 4.34 million for the quarter ended March 31, 2026, swinging from a net loss of USD 59,327 a year earlier.Interest earned on cash and investments held in the trust account totaled USD 4.44 million, while general and administrative costs were USD 132,030.Cash on hand was USD 347,720 at March 31, 2026, up from USD 223 at Dec. 31, 2025.Management said substantial doubt exists about its ability to continue as a going concern within one year, tied to completing an initial business combination within its 24-month window.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Drugs Made in America Acquisition II Corp. published the original content used to generate this news brief via EDGAR","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDLcfh50g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMII","DMIIU","DMAA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627923779","title":"Drugs Made in America Acquisition II posts FY25 net income of $4.2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2627923779","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627923779?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:11","pubTimestamp":1776283882,"startTime":"0","endTime":"0","summary":"Drugs Made in America Acquisition II posted net income of USD 4.2 million for fiscal 2025, driven by USD 4.9 million of interest earned on cash and investments held in the trust account.Revenue was not reported, as the SPAC had not generated operating revenues to date.General and administrative costs totaled USD 488,385, while a USD 812,113 provision for credit losses reflected a full reserve against amounts due from the sponsor.Management said conditions raised substantial doubt about its ability to continue as a going concern within one year after the financial statements are issued.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Drugs Made in America Acquisition II Corp. published the original content used to generate this news brie","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL3vSnT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMAA","DMII","DMIIU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624968664","title":"Drugs Made in America Acquisition II issues $1.4 million convertible notes financing deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2624968664","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624968664?lang=en_us&edition=fundamental","pubTime":"2026-04-04 04:34","pubTimestamp":1775248467,"startTime":"0","endTime":"0","summary":"Drugs Made in America Acquisition II entered into a definitive investment agreement on March 24, 2026 for a contemplated convertible notes financing.Company issued an interim convertible note of USD 0.3 million on March 30, 2026 to Alpha Multi Family Office.Note matures nine months from issuance, carries no interest.Investor can convert principal at business combination into shares at 35% discount to market price at conversion.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Drugs Made in America Acquisition II Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 03, 2026, and is so","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nNDLWvCKf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMIIU","DMII","DMAA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624549999","title":"Drugs Made in America Acquisition II delays annual report filing, targets April 15 deadline","url":"https://stock-news.laohu8.com/highlight/detail?id=2624549999","media":"Reuters","labels":["dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624549999?lang=en_us&edition=fundamental","pubTime":"2026-04-02 04:06","pubTimestamp":1775073978,"startTime":"0","endTime":"0","summary":"Drugs Made in America Acquisition II reported it will miss deadline for its Form 10-K for fiscal year ended Dec. 31, 2025.Delay was attributed to inability to compile all information needed for financial statements and related disclosures without unreasonable effort or expense.Filing indicated no anticipated significant change in results of operations versus prior-year period.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Drugs Made in America Acquisition II Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained there","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL5bnzTr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMIIU","DMII","DMAA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":10,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/DMIIU\",params:#limit:6,delay:false,,,undefined,":[]}}